Alzheimer's drug lecanemab hailed as momentous breakthrough

Argentina Noticias Noticias

Alzheimer's drug lecanemab hailed as momentous breakthrough
Argentina Últimas Noticias,Argentina Titulares
  • 📰 bbchealth
  • ⏱ Reading Time:
  • 34 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 63%

Lecanemab is the first drug to remove damage, but there are questions around its impact, side effects and use.

There is debate among scientists and doctors about the "real world" impact of lecanemab.

Dr Susan Kohlhaas, from Alzheimer's Research UK, said it was a "modest effect... but it gives us a little bit of a foothold" and the next generation of drugs would be better. Dr Elizabeth Coulthard, who treats patients at North Bristol NHS Trust, says that people have, on average, six years of living independently once mild cognitive impairment starts.

The emergence of drugs that do alter the course of the disease asks big questions of whether the health service is ready to use them. "There's an enormous gulf between current service provision and what we need to do, to deliver disease modifying therapies," said Dr Coulthard.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

bbchealth /  🏆 143. in US

Argentina Últimas Noticias, Argentina Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Second death linked to potential antibody treatment for Alzheimer’s diseaseExclusive: A 65-year-old woman who was receiving a promising experimental treatment to slow the cognitive decline caused by her early Alzheimers disease recently died from a massive brain hemorrhage that some researchers link to the drug.
Leer más »

At Least Two Deaths Have Now Been Linked to an Experimental Alzheimer's TreatmentAt Least Two Deaths Have Now Been Linked to an Experimental Alzheimer's TreatmentAn investigative report suggests that lecanemab can raise the risk of severe brain bleeding when taken with a blood thinner.
Leer más »

Experimental drug appears to slow progression of Alzheimer's disease in clinical trial but raises safety concerns | CNNExperimental drug appears to slow progression of Alzheimer's disease in clinical trial but raises safety concerns | CNNThe experimental drug lecanemab shows 'potential' as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association with certain serious adverse events.
Leer más »

🏠 Don’t miss your tax break | Morning Newsletter🏠 Don’t miss your tax break | Morning NewsletterDaily News | 🏠 Don’t miss your tax break | Morning Newsletter
Leer más »

Are you missing out on a Philly tax break?Are you missing out on a Philly tax break?One in five of the city's 324,000 owner-occupied homes isn’t enrolled in any of its tax relief programs, meaning those homeowners collectively pay $73 million more in taxes than they should.
Leer más »



Render Time: 2025-04-13 13:29:31